Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Evotec SE

SG&A Expenses: A Tale of Two Biotech Giants

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: Gilead Sciences, Inc. and Evotec SE, from 2014 to 2023.

Gilead Sciences, Inc.: A Steady Climb

Gilead Sciences, a leader in antiviral drugs, has seen its SG&A expenses rise steadily over the past decade. From 2014 to 2023, Gilead's expenses increased by over 100%, reflecting its expansive growth and strategic investments. By 2023, Gilead's SG&A expenses reached approximately $6.09 billion, underscoring its commitment to maintaining a robust operational framework.

Evotec SE: A Rapid Ascent

In contrast, Evotec SE, a prominent player in drug discovery, experienced a more dramatic increase in SG&A expenses, surging by nearly 900% over the same period. This rapid growth, culminating in expenses of around $169 million in 2023, highlights Evotec's aggressive expansion and scaling efforts.